In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on ProQR (PRQR – Research Report), with a price target of $5.00. The company's shares closed last Thursday at $0.67, close to its 52-week low of $0.67. According to TipRanks.com, Wolleben has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -26.3% and a 16.3% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals. ProQR has an analyst consensus of Moderate Buy, with a price target consensus of $3.10.
https://www.tipranks.com/news/blurbs/jmp-securities-reiterates-a-buy-rating-on-proqr-prqr?utm_source=advfn.com&utm_medium=referral
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more ProQR Therapeutics NV Charts.
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more ProQR Therapeutics NV Charts.